EUCTR2006-005143-28-DK进行中（未招募）1 期
Effects of HMG-CoA-reductase inhibition (atorvastatin) on renal sodium excretion, renal hemodynamics, tubular function and vasoactive hormones in healthy subjects under diet with normal and high sodium content.
Medicinsk Forskning0 个研究点开始时间: 2006年10月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men and women, age 20-50 years, BMI<30, for women use of anticonception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinical or anamnestic signs of disease of the heart, lungs, kidney, liver, brain or endocrine organs; abnormal findings at bloodscreening (hemoglobin, sodium, potassium, albumin, creatinin, bloodsugar, bilirubin, alaninaminotransferease, basic phosphatase); albuminuri; glucose in urine; cancer, hypertension, addiction to alcohol; medical treatment except per oral anticonception; pregnancy or breastfeeding; blooddonation one month before the trail.
研究者
相似试验
已完成
不适用
Effect of co-administration of HMG-CoA Reductase Inhibitor on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 Glu487Lys genotypes: randomized crossover trialangina pectorisJPRN-UMIN000013382Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu Univertisy44
进行中（未招募）
1 期
Treatment with simvastatin of growth and bone abnormalities in children with Noonan syndromeEUCTR2016-000647-14-FRniversity Hospital Toulouse62
已完成
3 期
Secondary prevention of HMG-CoA reductase inhibitor against strokeIschemic strokeJPRN-C000000207Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences3,000
进行中（未招募）
不适用
Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion - FluvaEDerectile dysfunction due to vascular impairmentEUCTR2006-000284-28-DEniversitätsklinikum des Saarlandes
已完成
不适用
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 SecretionHydroxymethylglutaryl-CoA Reductase InhibitorsDiabetes Mellitus, Type 2NCT03018444University Hospital, Gentofte, Copenhagen15